D-0237-2025 Class II Ongoing

Recalled by Glenmark Pharmaceuticals Inc., USA — Mahwah, NJ

FDA drug recall D-0237-2025 was initiated by Glenmark Pharmaceuticals Inc., USA on Jan 29, 2025 and is designated Class II. Reason for recall: CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit. The recall status is ongoing. Affected quantity: 39,168 bottles.

Recall details

Product Type
Drugs
Report Date
Feb 26, 2025
Initiation Date
Jan 29, 2025
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
39,168 bottles

Product description

Atomoxetine Capsules, USP, 100 mg, 30 capsule bottles, Rx Only, Manufactured for: Glenmark Pharmaceuticals Inc., NJ, USA, Product of India, NDC 68462-271-30.

Reason for recall

CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.

Distribution pattern

Nationwide within the U.S

Code information

Lot Numbers: 19234955, 19234956, Exp.: 11/2025; 19240971, Exp.: 2/2026; 19241864, Exp.: 4/2026.

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0237-2025
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0237-2025. Report a data issue: hello@regdatalab.com.